ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 25 Sep 2023
Last Updated on 25 Sep 2023
A- A+
Guidance Recommendations
The Ministry of Health’s Medical Technology Advisory Committee has recommended subsidy for sirolimus-coated percutaneous transluminal coronary angioplasty balloon catheters (SCBs) in patients with coronary artery disease (CAD), where percutaneous coronary intervention (PCI) is indicated when:

  • SCB is used as an alternative to drug-eluting coronary stents in certain lesions (such as in-stent restenosis [ISR], small vessel [e.g. < 2.5 mm], or long diffuse disease [e.g. >30 mm]) where:
    • The insertion of drug-eluting coronary stents is not appropriate or technically possible; or
    • There are clinical reasons to minimise duration of antiplatelet treatment (e.g. increased risk of bleeding, need for surgical intervention); OR
  • Paclitaxel-coated percutaneous transluminal coronary angioplasty balloon catheters (PCB) have previously been used but failed (e.g. recurrent ISR previously treated with PCB, challenging coronary anatomy, unavailable size or length of PCB).

Funding status

SCB is recommended for subsidy for treatment of coronary lesions in patients with CAD, in line with the abovementioned recommendations. Subsidies apply only to models listed in the Annex of this guidance.


SCBs for patients with CAD SCBs for patients with CAD Annex